Rivoglitazone

Overview

Rivoglitazone (R-106056) is an orally active, selective PPARγ agonist with an EC 50 of 0.22 μM for hPPARγ . Rivoglitazone regulates fatty acid storage and uptake, glucose homeostasis, and cardiac glucose/fatty acid metabolism. Rivoglitazone reduces levels of hyperglycemia, hyperinsulinemia, and hypertriglyceridemia, decreases hepatic glucose production, and accelerates plasma triglyceride clearance. Rivoglitazone induces a reduction in glycated hemoglobin A 1 C, while causing peripheral edema and weight gain. Rivoglitazone can be used in research related to type 2 diabetes.

Application

Products | Products > Disease Areas > Type 2 Diabetes | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Glucose Metabolism | Products > Disease Areas > Lipid Metabolism | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > Vitamin D Related/Nuclear Receptor | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Research Areas > Metabolic Disease | Products > Research Areas > Cardiovascular Disease | Products > Signaling Pathways > PPAR

Product Information

• Catalog No.: HY-106181
• CAS No.: 185428-18-6
• Molecular Formula: C20H19N3O4S
• Molecular Weight: 397.45
• Purity: 98.59%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Availability: In-stock

Source

Original product source